Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

Top Ten Research Reports of 2003

7. Continued Reverse Transcriptase Inhibitor Therapy Is Sufficient to Maintain Short-Term Partial Suppression of Multi-Drug Resistant Viremia

February 2004

Deeks S. G., Martin J. N., Hoh R. et al. Continued Reverse Transcriptase Inhibitor Therapy Is Sufficient to Maintain Short-Term Partial Suppression of Multi-Drug Resistant Viremia. Presented at: 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston, Mass. Abstract 640.


Background

Just when we thought we understood the fundamentals of HIV drug resistance, along comes a study that teaches us how much we still have to learn. We do know for a fact that it is not uncommon to observe patients on treatment who have viral loads well below their pre-therapy levels and CD4 cell counts that remain improved, yet who have low-level viremia and mutations to their current regimen.

A possible explanation for this common phenomenon is that the mutations the virus has developed have come at a cost to viral pathogenicity (i.e., the virus becomes less fit and therefore less able to replicate). This also explains why, when an antiretroviral regimen is discontinued in such patients, their viral load typically shoots up, their CD4 cell count plummets and resistant virus is supplanted by more pathogenic, wild-type virus -- Darwinian evolution over the course of a few weeks.


What Is New Here?

In a study presented at CROI 2003, Steven Deeks and colleagues closely observed what occurred when 20 patients with persistent, detectable, multi-drug-resistant viremia, while on stable antiretroviral therapy with a protease inhibitor and nucleosides for at least one year, either stopped their PI (n=15) or their nucleosides (n=5). The choice of which therapy was to be discontinued was based on the toxicity a patient was experiencing at the time of study entry.

Advertisement
What happened next will explain why this is one of 2003's most critical studies: 13 of the 15 patients who stopped their PI had both stable viral loads and CD4 cell counts after 16 weeks. Their toxicities improved, as did their lipids. PI mutations were no longer seen on genotype testing, since the selective pressure from the PI was gone and the risk of accumulation of new PI-associated resistance was reduced. In contrast, the five subjects who discontinued their NRTIs experienced a significant rise in their viral loads and an average 97-cell drop in their CD4 cell counts.


The Bottom Line

This study overturns many of our assumptions about resistance. Few would have accurately predicted the outcome observed by the investigators. The implication here is that the nucleosides may be doing more than we have ever recognized, even when resistance to these drugs is present. Practically speaking, these data suggest that for similar patients, the removal of a protease inhibitor and the maintenance of the nucleosides may be an option to prevent the cultivation of further PI resistance and limit toxicity. Periodic PI administration may help keep viral loads down and inevitable nucleoside failure at bay. In addition, continuation of "failing" nucleosides, as is commonly done with 3TC, may be a prudent approach to salvage therapy.

On a theoretical level, these preliminary data help us appreciate that resistance is not black and white, that partial antiviral effects may persist and that the impact of resistance on viral fitness may increasingly play a role in our treatment decision making.

For a complete index of The Body Pro's HIV JournalViews, click here!

Please note: Knowledge about HIV changes rapidly. Note the date of this article, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this article.

© 2004 Body Health Resources Corporation




  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

This article was provided by TheBodyPRO.com. It is a part of the publication HIV JournalView.
 

Tools
 

Advertisement